Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/117522
Title: Lack of a 5.9 kDa peptide C-terminal fragment of fibrinogen α chain precedes fibrosis progression in patients with liver disease
Author: Marfà Bruix, Santiago
Crespo Conde, Gonzalo
Reichenbach Marinkovic, Vedrana
Forns, Xavier
Casals Mercadal, Gregori
Morales Ruiz, Manuel
Navasa, Miquel
Jiménez Povedano, Wladimiro
Keywords: Malalties del fetge
Marcadors bioquímics
Hepatitis C
Trasplantament hepàtic
Cirrosi hepàtica
Assaigs clínics
Liver diseases
Biochemical markers
Hepatitis C
Hepatic transplantation
Hepatic cirrhosis
Clinical trials
Issue Date: 2-Oct-2014
Publisher: Public Library of Science (PLoS)
Abstract: Early detection of fibrosis progression is of major relevance for the diagnosis and management of patients with liver disease. This study was designed to find non-invasive biomarkers for fibrosis in a clinical context where this process occurs rapidly, HCV-positive patients who underwent liver transplantation (LT). We analyzed 93 LT patients with HCV recurrence, 41 non-LT patients with liver disease showing a fibrosis stage F≥1 and 9 patients without HCV recurrence who received antiviral treatment before LT, as control group. Blood obtained from 16 healthy subjects was also analyzed. Serum samples were fractionated by ion exchange chromatography and their proteomic profile was analyzed by SELDI-TOF-MS. Characterization of the peptide of interest was performed by ion chromatography and electrophoresis, followed by tandem mass spectrometry identification. Marked differences were observed between the serum proteome profile of LT patients with early fibrosis recurrence and non-recurrent LT patients. A robust peak intensity located at 5905 m/z was the distinguishing feature of non-recurrent LT patients. However, the same peak was barely detected in recurrent LT patients. Similar results were found when comparing samples of healthy subjects with those of non-LT fibrotic patients, indicating that our findings were not related to either LT or HCV infection. Using tandem mass-spectrometry, we identified the protein peak as a C-terminal fragment of the fibrinogen α chain. Cell culture experiments demonstrated that TGF-β reduces α-fibrinogen mRNA expression and 5905 m/z peak intensity in HepG2 cells, suggesting that TGF-β activity regulates the circulating levels of this protein fragment. In conclusion, we identified a 5.9 kDa C-terminal fragment of the fibrinogen α chain as an early serum biomarker of fibrogenic processes in patients with liver disease.
Note: Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0109254
It is part of: PLoS One, 2014, vol. 9, num. 10, p. e109254
Related resource: https://doi.org/10.1371/journal.pone.0109254
URI: http://hdl.handle.net/2445/117522
ISSN: 1932-6203
Appears in Collections:Articles publicats en revistes (Biomedicina)
Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
653193.pdf717.32 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons